Keros Therapeutics will use the proceeds from the Partners Healthcare and Medison Pharma-backed round to push its rare muscle disease drugs into clinical trials.
Keros Therapeutics, a US-based developer of treatments for rare muscle diseases, has collected $23m in a series B round that included pharmaceutical marketing firm Medison Pharma and care provider Partners Healthcare.
Arkin Bio Ventures, part of healthcare investment holding company Arkin Holdings, and Global Health Sciences Fund, a venture capital fund set up by Quark Ventures and investment bank GF Securities, also took part. Partners Healthcare invested through corporate venturing unit Partners Innovation Fund.
Founded in 2016, Keros is working…
